From The Source

Radiopharm Theranostics: Australian Ethics Committee approval to expand PD-L1 nanobody (RAD204) Phase 1 Trial in multiple tumor types

0 minute read

Pharma/Biotech

By

Cate Swannell

End of content

No more pages to load

Log In Register ×